COMPPARE Newsletter: Fall/Winter 2022-23

A Message from Dr. Nancy Mendenhall

I am excited to share with you that on October 31, 2022, COMPPARE closed enrollment with a total of 2,524 participants (1,024 photon patients and 1,500 proton patients; 900 pragmatic, 600 randomized)! Read Dr. Mendenhall’s message.

Partner Site Spotlight: The MUSC Hollings Cancer Center

MUSC’s Hollings Cancer Center, one of 71 National Cancer Institute-designated cancer centers in the nation, has the added distinction of being the only such center in South Carolina. Follow the conversation here.

COMPPARE Completes Patient Enrollment

After four years and 2,524 enrolled patients, the COMPPARE team officially closed patient accrual to the study on October 31, 2022. Read about this important achievement.

What’s Next for COMPPARE?

The study has closed enrollment, but the late outcomes of COMPPARE will be far more important than its early outcomes, for patients as well as physicians and insurers. Find out why participation for a minimum of 3 years and up to 10 years is vital to our success – learn more.

A Lapse in Screening Can be Costly

Proton BOB’s Bob Marckini discusses how skipping simple annual screening tests can result in missing prostate cancer (and other diseases) at early stages, when they can be more easily treated, often with curative results – read all about it.

Participants, Stay Current with Us!

Would you like to know about COMPPARE research updates, patient payment information, the VTOC portal, and providing survey input? Visit the new COMPPARE Participant page.

Research reported in this newsletter was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-2017C1-0422). The views, statements, and opinions presented in this newsletter are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors, or Methodology Committee.